My Employer Dropped GLP-1 Coverage for Weight Loss: What Are My Options?

When an employer drops coverage for weight-loss GLP-1 drugs such as Wegovy, Zepbound or Saxenda, your health plan will simply deny any prescription written for obesity. Diabetes coverage usually stays in place, but you could be left paying the full $1,000-plus list price out of pocket. You still have options: file an appeal, request an exception, use manufacturer $25 savings cards if you have any coverage at all, or switch to self-pay programs like LillyDirect® and NovoCare® that cap monthly costs in the $299-$449 range. Pair those moves with pre-tax HSA/FSA dollars and careful timing around open enrollment to keep therapy affordable.

• About 12% of large U.S. firms that do not cover GLP-1s today say they dropped the benefit within the last year (kff.org).
• Coverage for GLP-1s used to treat diabetes (for example Ozempic) almost always continues even when weight-loss coverage disappears.
• The Wegovy list price is $1,349.02 per 28-day box, while Zepbound’s is $1,086.37 (novocare.com).
• Manufacturer savings cards can lower your cost to as little as $25 a month when you still have any commercial coverage (wegovy.com).
• LillyDirect® self-pay pricing for Zepbound starts at $299 per month, and NovoCare® charges $349 per month for Wegovy 0.25-2.4 mg (lilly.com).
• The Medicare GLP-1 Bridge caps Wegovy at $50 a month for Part D enrollees from July 1 2026 through December 2027 (wegovy.com).

What losing GLP-1 coverage really means

Your plan now treats weight-loss GLP-1 prescriptions as non-covered, so the pharmacy will reject the claim at the counter. You may still fill the prescription, but you will owe the full “cash” or list price unless you apply a savings option discussed below.

GLP-1 is… a class of injectable or oral medications that mimic glucagon-like peptide-1, a gut hormone that reduces appetite and slows stomach emptying. When used for chronic weight management, FDA-approved brands include Wegovy (semaglutide), Saxenda (liraglutide) and Zepbound (tirzepatide).

Why employers are cutting weight-loss coverage

Cost pressure tops the list. The average wholesale price for Wegovy remains $1,349 per four-pen box, and Zepbound sits at $1,086 (novocare.com). When a large share of employees qualify, yearly spend can rival that of high-cost specialty drugs.

Survey data confirm the trend: only 18% of large firms (≥200 workers) still cover GLP-1s for weight loss in their largest plan, and 12% of the firms that do not cover the drugs say they dropped coverage in the past 12 months (kff.org).

Budget cycles matter. Many employers reassess formularies each spring for the plan year that begins the following January, so abrupt terminations often coincide with open enrollment notices.

Diabetes prescriptions are a different story

Coverage almost always continues when the drug is prescribed for type 2 diabetes. Plans consider diabetes treatment a medical necessity, whereas weight loss may be viewed as elective.

If you develop diabetes while on a weight-loss GLP-1, your provider can update the diagnosis code. A new prior authorization may still be required, but approval rates are high because the label is FDA-approved for diabetes.

How to appeal or request an exception

Start with your denial letter. It lists the reason (for example, “plan exclusion for obesity drugs”) and the window-typically 30 or 60 days-to file an appeal.

Key elements of a strong appeal:

• Letter of medical necessity from your prescriber detailing BMI, comorbidities (sleep apnea, hypertension), past weight-loss attempts and current response to the GLP-1.
• Supporting guidelines, such as American Diabetes Association or Endocrine Society statements.
• Any plan language that promises coverage when a drug is “medically necessary” or after trying alternatives.

If the internal appeal fails, you may request an independent external review. Self-insured employers must follow federal external review rules, while fully insured plans follow state rules. Instructions appear in the plan booklet.

Manufacturer savings cards, Medicare Bridge and self-pay pricing

If you still have any commercial coverage, a $25 card is usually the cheapest route. Both Novo Nordisk and Eli Lilly cap monthly out-of-pocket costs when the drug remains on the formulary, subject to maximum savings of $100-$200 each month (wegovy.com).

Self-pay programs bypass insurance entirely. LillyDirect® delivers Zepbound to your door starting at $299 per month for the 2.5 mg starter dose and $449 for higher doses (lilly.com). NovoCare® ships Wegovy for $349 per month (0.25-2.4 mg) after December 31 2026 (wegovy.com).

Medicare GLP-1 Bridge: From July 1 2026 through December 31 2027, eligible Part D enrollees pay just $50 per month for any Wegovy dose (wegovy.com).

Cash-pay tactics: discount cards, HSAs and timing

Discount cards: Pharmacy coupons can shave 5-20% off the official list price at retail chains. Always compare the Rx.com discount price with the manufacturer’s self-pay offer to see which wins.

HSA/FSA dollars: GLP-1 prescriptions are eligible medical expenses. Contributing the 2026 HSA maximum of $4,400 for self-only coverage can offset hundreds of dollars in taxes.

High-deductible reset: If you are in a high-deductible health plan, filling a large prescription in December can count toward both this year’s deductible and next year’s out-of-pocket cap if the plan offers a “deductible carry-over.” Check your summary plan description.

Open enrollment strategy: During open enrollment, compare the formulary of every plan option. Some employers offer a higher-premium plan that still covers weight-loss GLP-1s. Run the math: a $100 higher monthly premium may be cheaper than paying cash for the drug.